-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Osemitamab in Solid Tumor
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Osemitamab in Solid Tumor report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Osemitamab in Solid Tumor Drug Details: Osemitamab (TST-001) is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – TST-005 in Rectal Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - TST-005 in Rectal Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.TST-005 in Rectal CancerDrug Details:TST-005 is under development for the treatment of solid...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – XC-268BG
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data to allow you to track and predict specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using a combination of machine learning and proprietary models. Likelihood of Approval (LoA) - Industry XC-268BG Drug Details XC-268BG is under development for the treatment of lung fibrosis after...